Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00088166
Status:
COMPLETED
Last Update Posted:
2014-08-13
First Post:
2004-07-20
Brief Title:
XERECEPT hCRF for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Sponsor:
Celtic Pharma Development Services
Organization:
Celtic Pharma Development Services
Study Overview
Official Title:
A Phase III Randomized Double-Blind Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor hCRF to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone
Status:
COMPLETED
Status Verified Date:
2014-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the safety and efficacy of XERECEPT to dexamethasone Decadron a common treatment for symptoms of brain swelling edema This study is specifically aimed at patients who require chronic high doses of dexamethasone to manage symptoms
Detailed Description:
XERECEPT is not a potential treatment for cancer but may reduce the edema associated with tumors and as a result decrease neurological symptoms
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| XERECEPT | None | None | None |